Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.56 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.56 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.50 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.49 |
| ▸ | TEK | Q02763 | 1/20 | 0.49 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.49 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.49 |
| ▸ | FBP1 | P09467 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15393265 | 0.90 | EGFR (0.52) | EGFRRIPK2EPHB2ERBB2ERBB4 | |
| SCHEMBL15393266 | 0.90 | EGFR (0.52) | EGFRRIPK2EPHB2ERBB2ERBB4 | |
| SCHEMBL15391673 | 0.85 | EGFR (0.74) | EGFRRIPK2EPHB2ERBB2ERBB4 | |
| SCHEMBL15390935 | 0.83 | FBP1 (0.68) | EGFRRIPK2EPHB2ERBB2ERBB4 | |
| SCHEMBL22983813 | 0.81 | ABCG2 (0.61) | EGFRRIPK2EPHB2ERBB2ERBB4 | |
| SCHEMBL1418829 | 0.81 | EGFR (0.60) | EGFRERBB2KDRTEKEPHA2 | |
| SCHEMBL31472871 | 0.81 | EGFR (0.58) | EGFRRIPK2EPHB2ERBB2ERBB4 | |
| SCHEMBL15391257 | 0.81 | EGFR (0.58) | EGFRRIPK2EPHB2ERBB2ERBB4 | |
| SCHEMBL1418146 | 0.80 | EGFR (0.59) | EGFRERBB2KDRTEKEPHA2 | |
| SCHEMBL21835520 | 0.80 | EGFR (0.56) | EGFRRIPK2EPHB2ERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550738-B2 | Bicyclic compounds as kinases inhibitors | TELIGENE LTD. (CN) | 2017-01-24 | — | — | US | disclosed |
| US-20150126537-A1 | BICYCLIC COMPOUNDS AS KINASES INHIBITORS | TELIGENE LTD. (CN) | 2015-05-07 | — | — | US | disclosed |
| WO-2013173254-A1 | BICYCLIC COMPOUNDS AS KINASES INHIBITORS | ZHANG DAWEI (US) | 2013-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126537-A1 | BICYCLIC COMPOUNDS AS KINASES INHIBITORS | MAP3K20, MAP3K1, MAP3K5 | EGFR 1432/4885RIPK2 378/4885EPHB2 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.